Neumora Therapeutics, Inc. Common Stock (NMRA) Stock Price
NMRAStock
$0.47−73.38%52W
Market Cap$89.03M
P/E—
PEG Ratio—
Div yield—
Beta3.11
NMRA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-86.57%
Price vs S&P 500 (4W)-30.19%
VGM Score26.51
NMRA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.24 | -$0.23 | +5.34%(+$0.01) | |
| Q1 2026 | -$0.31 | -$0.30 | +3.23%(+$0.01) | |
| Q4 2025 | -$0.33 | -$0.35 | -7.01%(-$0.02) | |
| Q3 2025 | -$0.34 | -$0.35 | -4.29%(-$0.01) | |
| Q2 2025 | -$0.37 | -$0.33 | +10.40%(+$0.04) |
NMRA Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.07
4.07
4.07
4.07
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
NMRANeumora Therapeutics, Inc. Common Stock | — | — | D | — | — | — | — | $0.47 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Neumora Therapeutics, Inc. Common Stock
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for neuropsychiatric and neurodegenerative diseases. Its pipeline consists of seven clinical and preclinical programs targeting new mechanisms of action in underserved areas of neuroscience. The company aims to address significant unmet medical needs through its differentiated approach to brain disease treatment.